Endo to purchase Par Pharmaceutical for US$8.05bn

Published: 19-May-2015
Finance Pharmaceutical

Expanding generics business, product portfolio, pipeline and manufacturing capabilities


Endo International, which has its global headquarters in Dublin, Ireland, is to buy privately held Par Pharmaceutical Holdings for US$8.05bin, in a move that will significantly expand Endo's generics business as well as driving long-term revenue growth.

The transaction has been unanimously approved by both Boards of Directors and is expected to be completed in the second half of this year. Endo will pay around $1.55bn (18 million shares) in equity and $6.50bn in cash to Par shareholders.

Rajiv De Silva, President and CEO of Endo said: 'This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive gross margin products while also transforming Endo, creating a powerful corporate platform for future growth and strategic M&A.'

Par Chief Executive Paul Campanelli will join Endo to lead the generics business. He said the two companies share the same goal of 'developing and commercialising generic drugs in areas of greatest revenue potential, complex formulations and longer life cycles.'

  • Companies:
  • Par Pharmaceutical Companies
  • Endo Pharmaceuticals
See more

You may also like

Finance

Endo buys portfolio of branded and generic products

Read more
Acquisition supports continued growth in South Africa and adds some 60 on-market products and nearly 70 R&D pipeline programmes

Trending Articles

  1. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  2. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
  3. Dual-chamber packaging systems as a simplification factor in the supply chain Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
  4. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
  5. AbbVie's Elahere approved for platinum-resistant ovarian cancer by the European Commission Elahere is the first FRα-targeting antibody-drug conjugate (ADC) to be approved in Europe for platinum-resistant ovarian cancer

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Finance

Endo buys portfolio of branded and generic products

Acquisition supports continued growth in South Africa and adds some 60 on-market products and nearly 70 R&D pipeline programmes
Finance

Valeant increases offer for Salix to US$15.8bn in cash

Endo withdraws its offer for the US manufacturer of gastrointestinal drugs
Finance

Endo submits offer to purchase Salix Pharmaceuticals for about US$15.7bn

Higher bid than Valeant's offer of $14.5bn in February
Finance

Endo to acquire DAVA Pharmaceuticals

Adds high-margin generics portfolio and robust near-term ANDA pipeline to Endo\'s existing generics portfolio
Finance

Endo to buy Mexican speciality pharmaceuticals company Somar

Adds a strong growth platform in Mexico, a proven sales team and scalable manufacturing facilities
Manufacturing

Par Pharmaceutical to buy JHP Pharmaceuticals

Adds sterile injectable products to its portfolio
Finance

Endo to buy Paladin Labs for US$1.6bn

The firm will expand its presence in Canada and emerging markets
Subscribe now